2020
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, Walsh AM, Baxi V, Pandya D, Baradet T, Locke D, Wu Q, Reilly TP, Phillips P, Nagineni V, Gianino N, Gu J, Zhao H, Perez-Gracia JL, Sanmamed MF, Melero I. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nature Medicine 2020, 26: 688-692. PMID: 32405062, PMCID: PMC8127102, DOI: 10.1038/s41591-020-0856-x.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalBiomarkers, PharmacologicalBiomarkers, TumorCell Cycle CheckpointsCohort StudiesFemaleHumansInterleukin-8MaleNeoplasmsNeutrophil InfiltrationNeutrophilsPrognosisProtein Kinase InhibitorsRetrospective StudiesSurvival AnalysisTreatment FailureTumor MicroenvironmentUp-RegulationConceptsSerum IL-8 levelsImmune checkpoint inhibitorsIL-8 levelsAdvanced cancerSerum interleukin-8 levelsPhase 3 clinical trialsSerum interleukin-8Interleukin-8 levelsLarge-scale retrospective analysisNeutrophil infiltrationWorse prognosisClinical benefitPoor outcomeIndependent biomarkerTumor immunobiologyClinical trialsInterleukin-8Retrospective analysisPatientsCancerInhibitorsIpilimumabNivolumabEverolimusPrognosis
2014
A three‐gene panel that distinguishes benign from malignant thyroid nodules
Zheng B, Liu J, Gu J, Lu Y, Zhang W, Li M, Lu H. A three‐gene panel that distinguishes benign from malignant thyroid nodules. International Journal Of Cancer 2014, 136: 1646-1654. PMID: 25175491, DOI: 10.1002/ijc.29172.Peer-Reviewed Original ResearchAdultAgedBiomarkers, TumorCarbonic AnhydrasesDatasets as TopicDiagnosis, DifferentialDipeptidyl Peptidase 4FemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeuroendocrine Secretory Protein 7B2PrognosisReproducibility of ResultsThyroid NeoplasmsThyroid NoduleYoung Adult